The French biotech group Valneva finds itself at a critical juncture, with its share price pinned to a 52-week low of €2.34 as investors weigh a cascade of setbacks against a still-functioning commercial engine. The stock has shed nearly 40% of its value since the start of the year, driven by a combination of clinical disappointment, regulatory reversals, and mounting legal scrutiny.
The immediate trigger for the latest sell-off came from an unexpected corner. Goldman Sachs, which had previously maintained a neutral stance on the stock, issued a blunt downgrade to “Sell” and slashed its price target from €3.25 to €2.15. The investment bank cited a string of failures over the past twelve months, including the underwhelming VALOR trial for the Lyme disease vaccine candidate and the withdrawal of the Chikungunya vaccine IXCHIQ from the US market. The analyst move has reinforced the bearish narrative around a company that was once a high-flying pandemic-era story.
At the heart of the legal uncertainty is an investigation by the US law firm Pomerantz. The firm is examining potential securities law violations by Valneva’s management, focusing on a March 23, 2026 announcement regarding the Lyme vaccine. Valneva had presented the trial data as positive, but the vaccine candidate missed its primary endpoint. The stock cratered 37% that single day. While no formal lawsuit has been filed, the threat of litigation hangs over the stock, and investors are watching closely for any escalation.
Despite the clinical disappointment, Valneva’s deep-pocketed partner Pfizer has not abandoned the Lyme program. The US pharma giant continues to prepare regulatory submissions in both the United States and Europe, with filings expected by the end of the year. If approved, Valneva stands to receive milestone payments of $143 million in the near term, with an additional $100 million and future royalty streams potentially following. That potential windfall remains the single most valuable catalyst on the company’s horizon.
The regulatory picture for IXCHIQ, however, remains fractured. Valneva voluntarily withdrew its US license applications after the FDA suspended the license in August 2025. The UK’s MHRA followed suit in February 2026. But the vaccine is not a total write-off. Sales in Europe and Canada have actually been rising, and the company’s travel vaccine IXIARO continues to generate steady demand. Those commercial bright spots are helping to cushion the blow from the US regulatory setbacks.
Should investors sell immediately? Or is it worth buying Valneva?
Some analysts see value where Goldman sees risk. Jefferies maintains a Buy rating with a price target of $15, while Guggenheim also recommends buying the stock, albeit with a slightly reduced target of $11. The divergence in analyst opinion reflects the fundamental tension in the Valneva story: a company with a promising pipeline and a solid commercial base, but one that has stumbled badly in execution.
Beyond the courtroom and the clinic, Valneva is making quiet progress in emerging markets. In Brazil, a pilot campaign for IXCHIQ has already vaccinated over 12,000 people. The company is donating up to 500,000 doses to the Brazilian Ministry of Health, a move that builds goodwill and could pave the way for future commercial contracts in Latin America.
Financially, the company is not on the brink. Valneva reported total revenue of nearly €175 million for the last fiscal year and ended the period with roughly €110 million in cash. Management managed to reduce cash burn by 21%, a sign of discipline amid the turbulence. For the current year, the company has guided for total revenue of up to €170 million.
All eyes now turn to May 7, when Valneva will report first-quarter results. Guggenheim expects revenue of €49.1 million, slightly above consensus. The report will be a crucial test of whether the European business can compensate for the lost US opportunity. If the numbers show resilience, it could ease some of the downward pressure on the stock. But until the legal questions are resolved and the regulatory path for the Lyme vaccine becomes clearer, the shares are likely to remain under a cloud.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from April 26 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 26.
Valneva: Buy or sell? Read more here...
